AN ALLIANCE TO CREATE A WORLD LEADER IN HEALTHCARE AND CLINICAL RESEARCH
About MHP Partnership
Revive Research Institute is partnering with Michigan Healthcare Professionals (MHP) to further the goal of improving patient centered healthcare. The partnership of the two highly qualified, organization that share similar vision and values will accelerate development of innovative treatment strategies and improve patient’s healthcare.
MHP is a physician led and administered organization, with goals very similar to that of Revive Research Inc. The physicians at MHP are committed to patient’s wellbeing and always go an extra mile for ensuring patient’s safety. MHP places immense emphasis on solid team-work, following patient care protocols, and devising a treatment plan that is affordable for all patients.
The partnership will effectively expand the horizon for both organizations and the patients, by offering broader services, deeper therapeutic expertise, and enhanced patient care. With MHP’s brilliant physicians, and Revive’s experienced clinical research staff, dawn of a new era in therapeutic medicine
Dr. Jeffrey Margolis, MD.
President of MHP
Hematology, Oncology, Internal Medicine
CURING DISEASES AND CHANGING LIVES TOGETHER
What is MHP?
The MHP Board of Directors is responsible for the quality of care policies, the compliance of its physicians to follow best practice guidelines, and the metrics to monitor the outcomes of patient care. Michigan Healthcare Professionals is putting into practice what leaders in healthcare, as well as third-party purchasers of healthcare services, have been calling for within the modern practice of medicine.
About Partnership
The partnership brings together two rapidly growing organization with a common culture, and values centered at enhancing patient care. The patient’s welfare is at the heart of all operations carried out at both MHP and Revive Research Inc. MHP strives to offer the best possible treatment, whereas Revive aims to find cures to improve lives and cure diseases.
Our Doctors
Dr. Savitha Balaraman
Oncology | Principal Investigator
Sub-Investigators
Dr. Richard Zekman
Dr. Samer Ballouz
Dr. Lynette Sutkowi
Dr. Adil Akhtar
44344 Dequindre Road, Suite 260
Sterling Heights, MI 48314
Advanced Pancreatic Cancer
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer.
Breast Cancer
The Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA) study is a phase 3 trial assessing the safety and tolerability of TOL2506, combined with endocrine therapy, in premenopausal patients with HR+, HER2- negative breast cancer.
Diffuse Large B-Cell Lymphoma
MOR208C310 – Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP vs. R-CHOP only in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma
Efficacy of Cryotherapy Device with Oral Mucositis
A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer.
EGFRI-induced Acneiform Lesions in Metastatic Colorectal Cancer
EGFRI-induced Acneiform Lesions in Metastatic Colorectal Cancer
L-02-01 – Phase 2, multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of two strengths of LUT014 Gel topically applied qd for 4 weeks in mCRC patients with EGFRI induced Grade 2 acneiform lesions
Follicular Lymphoma
Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Indolent Non-Hodgkin’s Lymphoma
Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) – The COASTAL Study
Malignant Myeloid Hematologic Neoplasms
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients with Malignant Myeloid Hematologic Neoplasms.
Metastatic Castration-Sensitive Prostate Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Participants With DDR-Deficient Metastatic Castration-Sensitive Prostate Cancer.
Positive Oropharyngeal Cancer
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC).
Predicting Immunotherapy Efficacy
Predicting immunotherapy efficacy from analysis of pretreatment tumor biopsies. We hypothesize that the results from these experiments will show that the OncoPrism™ assay will be predictive of efficacy of immunotherapy. Pre-treatment samples will be utilized for these analyses.
Prevention of Chemotherapy-induced Myelosuppression
A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression.
Relapsed/Refractory Myelofibrosis
This is a Phase 2, multicenter, open-label study to determine the safety and tolerability of TL-895 in subjects with relapsed/refractory myelofibrosis, Janus kinase inhibitor intolerant myelofibrosis, and Janus kinase inhibitor treatment ineligible myelofibrosis.
Uterine Serous Carcinoma
Phase 2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 300 mg once daily (QD), in adult women with recurrent or persistent uterine serous carcinoma (USC).
Dr. Savitha Balaraman
32255 Northwestern Hwy., Suite 150
Farmington Hills, MI 48334
Advanced Pancreatic Cancer
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer
Breast Cancer
OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA): A Phase 3 Study Evaluating Ovarian Suppression Following Subcutaneous Administration of TOL2506 in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone–Receptor—Positive (HR+), human epidermal growth factor receptor 2 (HER2)–Negative Breast Cancer
Diffuse Large B-Cell Lymphoma
Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP vs. R-CHOP only in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma
Efficacy of Cryotherapy Device in Oral Mucositis
A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer.
EGFRI-induced Acneiform Lesions in Metastatic Colorectal Cancer
Phase 2, multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of two strengths of LUT014 Gel topically applied qd for 4 weeks in mCRC patients with EGFRI induced Grade 2 acneiform lesions
Follicular Lymphoma
Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Indolent Non-Hodgkin’s Lymphoma
Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) – The COASTAL Study
Malignant Myeloid Hematologic Neoplasms
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients with Malignant Myeloid Hematologic Neoplasms.
Metastatic Castration-Sensitive Prostate Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Participants With DDR-Deficient Metastatic Castration-Sensitive Prostate Cancer.
Positive Oropharyngeal Cancer (OPC)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)
Predicting Immunotherapy Efficacy
Predicting immunotherapy efficacy from analysis of pretreatment tumor biopsies. We hypothesize that the results from these experiments will show that the OncoPrism™ assay will be predictive of efficacy of immunotherapy. Pre-treatment samples will be utilized for these analyses.
Prevention of Chemotherapy-induced Myelosuppression
A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression.
Relapsed/Refractory Myelofibrosis
A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
Uterine Serous Carcinoma
Phase 2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 300 mg once daily (QD), in adult women with recurrent or persistent uterine serous carcinoma (USC).